Related references
Note: Only part of the references are listed.Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic
Pooria Safarzadeh Kozani et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2022)
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
Antonio Faiella et al.
JOURNAL OF ONCOLOGY (2022)
Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence
Nahlah Makki Almansour
FRONTIERS IN MOLECULAR BIOSCIENCES (2022)
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Caterina Gianni et al.
FRONTIERS IN ONCOLOGY (2022)
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Fatemeh Nasiri et al.
FRONTIERS IN IMMUNOLOGY (2022)
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Jingjing Qu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
Shivani Srivastava et al.
CANCER CELL (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer
Vignesh Sivaganesh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Christopher Sloas et al.
FRONTIERS IN IMMUNOLOGY (2021)
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Kuba Retecki et al.
CANCERS (2021)
CAR-macrophage: A new immunotherapy candidate against solid tumors
Yizhao Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Epidemiology of De Novo Metastatic Breast Cancer
Karen Daily et al.
CLINICAL BREAST CANCER (2021)
Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients
Yajun Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
A review of immune checkpoint blockade in breast cancer
Benedetta Pellegrino et al.
SEMINARS IN ONCOLOGY (2021)
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer
Rokana Taftaf et al.
NATURE COMMUNICATIONS (2021)
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
Shifaa M. Abdin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Mesothelin-targeted CAR-T cell therapy for solid tumors
Astero Klampatsa et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Reem Saleh et al.
SEMINARS IN CANCER BIOLOGY (2020)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
Christian M. Seitz et al.
ONCOIMMUNOLOGY (2020)
A population of proinflammatory T cells coexpresses αβ and γδ T cell receptors in mice and humans
Sarah C. Edwards et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
The therapeutic landscape for cells engineered with chimeric antigen receptors
Matthew MacKay et al.
NATURE BIOTECHNOLOGY (2020)
Recent Advances in Allogeneic CAR-T Cells
Dong Wook Kim et al.
BIOMOLECULES (2020)
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
Yuexian Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Human chimeric antigen receptor macrophages for cancer immunotherapy
Michael Klichinsky et al.
NATURE BIOTECHNOLOGY (2020)
Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
Yan Liu et al.
CELL PROLIFERATION (2020)
Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
Fabio Morandi et al.
CELLS (2020)
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Bassel Nazha et al.
FRONTIERS IN ONCOLOGY (2020)
Macrophages enter CAR immunotherapy
Madhura Mukhopadhyay
NATURE METHODS (2020)
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner et al.
MOLECULAR THERAPY (2020)
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer
Sabine Kasimir-Bauer et al.
FRONTIERS IN ONCOLOGY (2020)
CAR MACROPHAGES (CAR-M) ELICIT A SYSTEMIC ANTITUMOR IMMUNE RESPONSE AND SYNERGIZE WITH PD1 BLOCKADE IN IMMUNOCOMPETENT MOUSE MODELS OF HER2+SOLID TUMORS
Stefano Pierini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions
Li Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Triple negative breast cancer: special histological types and emerging therapeutic methods
Lu Cao et al.
CANCER BIOLOGY & MEDICINE (2020)
EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo
Lin Xia et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer
Mark Leick et al.
CANCER DISCOVERY (2019)
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Leticia De Mattos-Arruda et al.
CELL REPORTS (2019)
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Yuxin Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
Yulia Liubomirski et al.
FRONTIERS IN IMMUNOLOGY (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
Wenlong Zhang et al.
BRITISH JOURNAL OF CANCER (2019)
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
E. Krasniqi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
Julie Voeller et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2019)
Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
Rajat K. Das et al.
CANCER DISCOVERY (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe et al.
JCI INSIGHT (2019)
A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
Jing Wei et al.
CELLULAR IMMUNOLOGY (2018)
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy
Joana M. Murad et al.
CYTOTHERAPY (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
Yali Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2018)
Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
He Li et al.
CELL DEATH & DISEASE (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
David M. Goldenberg et al.
Oncotarget (2018)
Chimeric antigen receptors that trigger phagocytosis
Meghan A. Morrissey et al.
ELIFE (2018)
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
David A. Sallman et al.
HAEMATOLOGICA (2018)
The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
Ana Stojanovic et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chondroitin Sulfate Proteoglycan 4 and its Potential As an Antibody immunotherapy Target across Different Tumor Types
Kristina M. Ilieva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Si-Qi Qiu et al.
CANCER TREATMENT REVIEWS (2018)
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth et al.
NATURE (2018)
Emerging Cellular Therapies for Cancer
Sonia Guedan et al.
Annual Review of Immunology (2018)
p95HER2-T cell bispecific antibody for breast cancer treatment
Irene Rius Ruiz et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Kristen B. Long et al.
FRONTIERS IN IMMUNOLOGY (2018)
Making CAR T Cells a Solid Option for Solid Tumors
Andrea Schmidts et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression
Zhe Wang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2018)
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Tiara T. Byrd et al.
CANCER RESEARCH (2018)
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
Michal Mego et al.
ONCOTARGET (2017)
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Julian Andreev et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
Rin Ogiya et al.
ONCOTARGET (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
Spencer Park et al.
SCIENTIFIC REPORTS (2017)
Treatment of renal cell carcinoma: Current status and future directions
Pedro C. Barata et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Macrophages: sentinels and regulators of the immune system
Lars Franken et al.
CELLULAR MICROBIOLOGY (2016)
Role of tumor-associated macrophages in human malignancies: friend or foe?
Motohiro Takeya et al.
PATHOLOGY INTERNATIONAL (2016)
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer
M. Mego et al.
JOURNAL OF CANCER (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy
Amelia E. Firor et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2015)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes
Daniel J. O’Shannessy et al.
Oncotarget (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells
Ping Tang et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2014)
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Teemu T. Junttila et al.
CANCER RESEARCH (2014)
T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Claudia Geldres et al.
CLINICAL CANCER RESEARCH (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
Clemence Feneyrolles et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
Gary Tozbikian et al.
PLOS ONE (2014)
ICAM-1 as a molecular target for triple negative breast cancer
Peng Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Sritama Nath et al.
TRENDS IN MOLECULAR MEDICINE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Rachel E. Beard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer
Napa Parinyanitikul et al.
CLINICAL BREAST CANCER (2013)
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery
Xinping Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Julia Tchou et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types
Amit Chaudhary et al.
CANCER CELL (2012)
Molecular Mechanisms of Prolactin and Its Receptor
Charles L. Brooks
ENDOCRINE REVIEWS (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
Correction: Broad Expression Analysis of Human ANTXR1/TEM8 Transcripts Reveals Differential Expression and Novel Splizce Variants
Micaela Vargas et al.
PLoS One (2012)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Marco Erreni et al.
CANCER MICROENVIRONMENT (2011)
A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin αvβ3, ± Dacarbazine in Patients With Stage IV Metastatic Melanoma
Peter Hersey et al.
CANCER (2010)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
X. Ye et al.
ONCOGENE (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
Hongkui Jin et al.
CANCER RESEARCH (2008)
Integrin αvβ3-Targeted Cancer Therapy
Zhaofei Liu et al.
DRUG DEVELOPMENT RESEARCH (2008)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Antibodies, Fc receptors and cancer
Falk Nimmerjahn et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo
Tobias Martens et al.
CLINICAL CANCER RESEARCH (2006)
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy
T Zhang et al.
BLOOD (2005)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1
M Dalziel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
